See more : Nippon Kayaku Co., Ltd. (NPKYF) Income Statement Analysis – Financial Results
Complete financial analysis of AN2 Therapeutics, Inc. (ANTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AN2 Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Navin Fluorine International Limited (NAVINFLUOR.BO) Income Statement Analysis – Financial Results
- Zions Bancorporation, National Association (ZIONP) Income Statement Analysis – Financial Results
- BEWi ASA (BEWI.OL) Income Statement Analysis – Financial Results
- Champion Alliance International Holdings Limited (1629.HK) Income Statement Analysis – Financial Results
- Fovea Jewelry Holdings, Ltd (FJHL) Income Statement Analysis – Financial Results
AN2 Therapeutics, Inc. (ANTX)
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -77.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.87M | 29.51M | 16.91M | 6.02M | 4.89M |
| General & Administrative | 14.76M | 12.75M | 4.67M | 1.27M | 1.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 287.27K |
| SG&A | 14.76M | 12.75M | 4.67M | 1.27M | 289.00K |
| Other Expenses | 0.00 | -45.00K | -38.00K | -6.32M | 0.00 |
| Operating Expenses | 69.64M | 42.26M | 21.57M | 7.28M | 5.18M |
| Cost & Expenses | 69.64M | 42.26M | 21.57M | 7.28M | 5.18M |
| Interest Income | 0.00 | 1.35M | 69.00K | 3.00K | 0.00 |
| Interest Expense | 0.00 | 514.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 69.64M | 77.00K | 21.57M | 7.28M | 31.07M |
| EBITDA | 4.90M | -42.26M | 0.00 | -6.32M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -69.64M | -42.26M | -21.57M | -7.28M | -5.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.90M | 1.31M | 31.00K | -6.32M | -457.00K |
| Income Before Tax | -64.73M | -40.96M | -21.54M | -13.60M | -5.64M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 514.00K | -69.00K | -3.00K | -31.07K |
| Net Income | -64.73M | -41.47M | -21.47M | -13.60M | -5.64M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| EPS Diluted | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| Weighted Avg Shares Out | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
| Weighted Avg Shares Out (Dil) | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
AN2 Therapeutics to Participate at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December....
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an...
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research...
3 Penny Stocks To Buy With Just $750
Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky.
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
AN2 Therapeutics (NASDAQ: ANTX ) stock is taking a beating on Friday after the company provided an update on its EBO-301 Phase 2/3 study. AN2 Therapeutics notes that information comes from the Phase 2 study of epetraborole as an optimized background...
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today announced topline results from the Phase 2 part of the EBO-301 Phase 2/3...
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for...
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024. “The Phase...
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31,...
Source: https://incomestatements.info
Category: Stock Reports